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Abstract 
Objective: Previous research on the minimal clinically important difference (MCID) for depression and anxiety is based on population 
averages. The present study aimed to identify the MCID across the spectrum of baseline severity. 
Study Design and Settings: The present analysis used secondary data from 2 randomized controlled trials for depression ( n = 1,122) 
to calibrate the Global Rating of Change with the PHQ–9 and GAD–7. The MCID was defined as a change in scores corresponding to 
a 50% probability of patients "feeling better", given their baseline severity, referred to as Effective Dose 50 (ED50). 
Results: MCID estimates depended on baseline severity and ranged from no change for very mild up to 14 points (52%) on the 
PHQ–9 and up to 10 points (48%) on the GAD–7 for very high severity. The average MCID estimates were 3.7 points (23%) and 3.3 
(28%) for the PHQ–9 and GAD–7 respectively. 
Conclusion: The ED50 method generates MCID estimates across the spectrum of baseline severity, offering 
greater precision but at the cost of greater complexity relative to population average estimates. This has impor- 
tant implications for evaluations of treatments and clinical practice where users can use these results to tailor the 
MCID to specific populations according to baseline severities. © 2021 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
























Depression and anxiety are the most common mental
health problems worldwide [1] . In the absence of objec-
tive tests, self-report questionnaires are frequently used to
measure symptom change. However, uncertainty remains
about how much change on these questionnaires is clini-
cally meaningful. A first step toward conceptualizing clini-
cally meaningful improvement has been to define minimal
clinically important differences (MCID) – the smallest dif-
ference in scores that are of perceived benefit to patients
[2] . Although various methods of estimating important dif-
ferences on questionnaires exist, it is imperative to includeConflict of interest: None. 
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( http://creativecommons.org/licenses/by/4.0/ ) patients’ perceptions to define clinically meaningful change
[2 –4] , particularly where subjective experiences, such as
depression, and anxiety, are targeted. Anchor–based ap-
proaches, which anchor questionnaire outcomes onto pa-
tient reports of subjective improvement, are truly patient-
centered by incorporating the patients’ experiences [2] . 
Early work estimating the MCID using these meth-
ods for the Beck Depression Inventory-II demonstrated
baseline dependency [5 , 6] . Patients with a higher base-
line severity require larger changes to experience a sub-
jective improvement. Various methods exist to address this
problem (Supplementary Material A); however, 2 com-
monly used methods are the standardized mean differences
amongst those who report slight improvements compared
to those who feel the same or proportionate change - per-
centage change in symptoms relative to baseline [5 –9] .
Recent research has explored the MCID for depression
and anxiety on the Patient Health Questionnaire (PHQ-9)ess article under the CC BY license 























































































and Generalized Anxiety Disorder Scale (GAD-7) [10-12] .
Collectively, the research suggests that the MCID can be
defined as approximately 20% improvement , [5,9,12] . Al-
though providing a good rule-of-thumb, they are unable to
fully capture baseline dependency equally well across all
patients – the 20% estimate applies less well to patients
with lower baseline severity or patients with treatment re-
sistant depression with higher baseline severity [5,12] . This
is substantiated by research demonstrating a 51% disagree-
ment when comparing the 20% MCID to patient self-
reported improvement [13] . Standardized effect sizes have
been criticized for being difficult to interpret and providing
little clinical information [14] . Given this, there is a need
to further address baseline dependency when estimating
the MCID. In light of the above, we present a novel ap-
proach to estimate a baseline-dependent MCID for widely
used measures of depression and anxiety – the PHQ-9 and
GAD-7 [10 , 11] . 
2. Methods 
2.1. The sample 
The present study used data from two, multi-center
randomized controlled trials (RCTs): PANDA (What are
the indications for prescribing ANtiDepressants that will
leAd to a clinical benefit) and CoBalT. [15 , 16] PANDA
( n = 653) compared sertraline vs. placebo in primary care
patients where there was clinical equipoise about the ben-
efits of antidepressant medication [15] . CoBalT ( n = 469)
compared cognitive behavioral therapy (CBT) as an ad-
junct to usual care (pharmacotherapy) to usual care alone,
in primary care patients with treatment resistant depres-
sion [16] . The data was pooled across RCTs, resulting in
more observations at each level of baseline severity and
therefore increasing the precision of analyses. Data from
all treatment arms was used as we assume a stability be-
tween change in symptoms and subjective improvement,
irrespective of how the change in symptoms is brought
about. Pooling data from both RCT and across treatment
arms also increases the generalizability of the results. 
2.2. The 9-item patient health questionnaire (PHQ-9) and
the 7-Item generalized anxiety disorder scale (GAD-7) 
The PHQ-9 and GAD-7 are self-report questionnaire
assessing the severity of depression and anxiety symptoms
over the past 2 weeks, respectively [10 , 11] . The range for
the PHQ-9 is 0-27 and 0-21 on the GAD-7, with higher
scores indicating greater symptom severity. The PHQ-9 and
GAD-7 were completed at baseline, 2-, 6-, and 12-weeks
in PANDA [15] . In CoBalT, the PHQ-9 was measured at
baseline, 3-, 6-,9-, and 12-months whereas the GAD-7 was
collected at baseline, 6- and 12-months [16] . 2.3. Global rating of change (GRC) 
Both PANDA and CoBalT included the 1-item GRC
asking patients how they felt compared to when they were
last seen [15-18] . The GRC was measured at all follow-up
time points. CoBalT patients could respond: “I feel bet-
ter”, “I feel about the same”, and “I feel worse” [16] .
In PANDA, patients could respond: “I feel a lot better”,
“I feel slightly better”, “I feel about the same”, “I feel
slightly worse”, and “I feel a lot worse” [15] . For all mod-
els, groups were dichotomized into feeling better and not
feeling better, as the aim was to estimate the point at which
patients experience an improvement. The category not feel-
ing better consisted of patients who felt the same or worse.
2.4. Statistical analysis 
An extensive methodological justification can be found
in supplementary material A. All analyses were performed
in the R statistical programming language [19] . 
2.4.1. Modelling change across time 
Change across multiple follow-ups was calculated from
the previous timepoint (a rolling baseline), so at time t
the change is: x (t-1) – x t, where x t is the follow-up score
at timepoint t . Negative scores indicate deteriorations in
symptoms whereas positive scores indicate improvements
in symptoms. 
To establish that the GRC is an appropriate anchor,
Spearman rank correlation coefficients were estimated, ex-
amining the association between the categorical GRC and
change scores. Correlation coefficients ≥0.30 have been
deemed as appropriate [20] . This threshold was exceeded
across studies and time points ranging from -0.32 to -0.52
(Supplementary Material B). 
2.4.2. Generalized additive mixed models (GAMM) 
GAMMs provide a flexible approach to model complex,
interacting relationships although maximizing model fit.
A logistic GAMM was fitted, specifying the binary GRC
( better vs. not better ) as the outcome using the “mgcv”
package [21] . Change in symptom scores and baseline
severity were classed as predictors with an interaction term,
given the established importance of baseline dependency
[4 , 5 , 12] . Due to the repeated measurement, a random in-
tercept was included for patients [15 , 16] . There is a natural
variation in GRC responses between individuals – different
patients will be more or less likely to respond feeling bet-
ter or not better even when accounting for baseline severity
and change . Random effects can account for the correla-
tion between repeated observations of the same individual.
To deal with the intrinsic correlation between change and
baseline scores as well the bounded nature of the scales
thin plate splines with a monotonicity constraint were used
to model the combined effect of change and baseline sever-
ity on the response [21] . As the data were obtained from
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Table 1. Sociodemographic and clinical characteristics, stratified by study 
PANDA CoBalT 
n 653 469 
Age (years) 39.70 (14.93) 49.59 (11.70) 
Female 384 (59%) 339 (72%) 
Whitea 579 (89%) 459 (98%) 
Marital Status a 
Married or living as married 255 (39%) 248 (53%) 
Single 296 (45%) 89 (19%) 
Separated, divorced, or widowed 101 (15%) 132 (28%) 
In paid employment a 433 (66%) 206 (44%) 
Highest educational qualification a , b 
A level, higher grade or above 450 (69%) 217 (47%) 
GCSE, standard grade or other 169 (26%) 130 (28%) 
No formal qualifications 33 (5%) 116 (25%) 
Financial difficulty a 
Living comfortably or doing alright 364 (56%) 167 (36%) 
Just about getting by 204 (31%) 174 (37%) 
Finding it difficult or very difficult to make ends meet 84 (13%) 128 (27%) 
Number of life events in past 6 months 1.22 (1.19) 1.25 (1.15) 
SF-12 mental health subscale 32.47 (11.04) 28.60 (9.14) 
SF-12 physical health subscale 52.07 (9.70) 43.45 (13.47) 
Patient Health Questionnaire-9 12.00 (5.80) 16.59 (5.67) 
Generalized Anxiety Disorder Scale-7 9.43 (5.28) 11.75 (5.05) 
a Data missing for one person in Panda. 










































2 separate studies and collected over multiple follow-up
periods, a further model evaluated the effects of time and
study by adding these as covariates. Model summaries and
95% confidence intervals can be found in Supplementary
Material C and D, respectively. 
2.4.3. Effective dose 50 (ED50) 
In the present study we applied the ED50 as a new
method to estimate the MCID. ED50 is an interpretable
and well-validated measure used in drug safety and phar-
maceutical research to determine minimum thresholds for
effective therapeutic doses [22] . Applied to the current con-
text, the ED50 is the change in scores where there is a 50%
probability of patients reporting feeling better . The ED50
has face validity as an MCID as it identifies the smallest
point where a patient might be marginally more likely to
feel better than not . Further face validity is added to the
concept of using the ED50 as a MCID given that the low-
est bound of response to treatment is often defined as a
50% improvement [23] . Here, this principle is applied to
the subjective experience of improvement rather than the
symptom measure itself. From the GAMMs, we predicted
the probability of response and identified the change in
scores associated with 50% probability of feeling better .
A limit of 0 change was set, as it would be clinically un-
acceptable to classify symptom deteriorations as improved.The absolute MCIDs were converted to a percent change
from baseline. The ED25 and ED75 - the point at which
there is a 25% and 75% probability that the patient re-
ports feeling better - were also calculated as interval es-
timates, providing an index of variability of feeling better
under different clinically acceptable probabilities. Further-
more, the sensitivity, and specificity of the ED50 as well
as the agreement between the MCID and patient-reported
improvement were estimated. 
2.4.4. Standardized mean difference (SMD) 
To allow for comparisons with more traditional meth-
ods, the crude and standardized mean difference be-
tween those “feeling slightly better” and those “feeling
about the same” were examined in PANDA using the
“TableOne” package [7 –9 , 24] . These data were not avail-
able in CoBalT. 
3. Results 
3.1. Sample characteristics 
Baseline sociodemographic and clinical characteristics
of all patients recruited into the RCTs are presented in
Table 1 . Patients in PANDA had a lower clinical severity
at baseline, with moderate symptoms of depression and
mild anxiety. Patients in CoBalT had higher scores across























































































all measures with severe depression and moderate anxiety
scores. Table 2 shows the mean change associated with
GRC responses, stratified by study and follow-up. 
3.2. GAMM 
We found statistically significant effects of study and
time on the probability of feeling better. However, as might
be expected, these made little to the MCID estimates and
were therefore omitted from the final model for inter-
pretability and generalizability. Of note, the effects of study
on probability of feeling better appear to be driven by the
differing baseline severities of the two samples at time
point 1 due to their differing selection criteria. Combining
the datasets is advantageous as it provides rich data across
the distribution of baseline scores and the model produces
a weighted average that accounts for the number of obser-
vations in each study. 
3.3. ED50 
Table 3 shows the ED estimates for both questionnaires.
Across the PHQ–9 and GAD–7, patients with minimal
symptoms at baseline need no change to have at least
a 50% probability of feeling better; however, as severity
increases the ED estimates increase in incremental steps.
However, this is not a uniform, linear pattern, demonstrat-
ing the complexity of the effect change and baseline sever-
ity have on the probability of feeling better. 
The ED50 score averaged over patients coincides with
moderate depression (PHQ–9) and mild anxiety (GAD–
7).However, there was a large range of MCID estimates,
from 0 points (0%) up to 14 points (52%) on the PHQ-9,
and up to 10 points (48%) on the GAD–7. Larger changes
are needed on the GAD–7 than the PHQ-9 to feel better . 
The models could not predict higher probabilities of
feeling better amongst patients with very low baseline
severity on the GAD–7, given the marginal ability to im-
prove in symptoms. Patients would have to change more
than is possible to obtain high probabilities of improve-
ment. For clinical interpretation, equating these to 100%
change is reasonable. 
3.4. Sensitivity and specificity 
Table 4 demonstrates that the ED50 estimates shows
adequate sensitivity and specificity, providing a reasonable
estimate for the smallest change in scores needed to feel
better. The specificity of the ED50 was generally higher
than the sensitivity and did not fall below 0.70, which
could be deemed a clinically acceptable threshold. The
disagreement between GRC and improvements based on
the ED50 was 28.4% on the PHQ–9 and 28.9% on the
GAD–7. 3.5. SMD 
Table 5 shows the mean difference between those feel-
ing the same and those feeling slightly bette r was ˜ 2 points
on both questionnaires. The SMD on the PHQ–9 was ˜0.6
and ˜0.5 on the GAD–7. 
4. Discussion 
A patient-centered approach was taken to estimate the
MCID for widely used measures of depression and anxi-
ety. The MCID was defined in a novel way as the change
in scores that reflects at least a 50% probability that pa-
tients report feeling better . We produced MCID estimates
stratified by severity scores, which increased with baseline
severity in a non-linear manner, ranging from no change
for very mild up to 14 points (52%) on the PHQ-9 and
up to 10 points (48%) on the GAD–7 for high severity.
Across the sample, the average MCID estimates were 3.7
points (23%) and 3.3 (28%) for the PHQ–9 and GAD–7
respectively. For comparative purposes, the (standardized)
mean difference method was applied to PANDA yielding
estimates of ˜0.6 and ˜0.5 for the PHQ–9 and GAD–7 re-
spectively [7 –9] . 
Previous research modelling proportionate change sug-
gests the MCID is ˜ 20–30% improvement for moderately-
severe populations for depression and anxiety respectively
[5,12] . Specifically, for patients of a moderate baseline
severity a MCID of 21% change on the PHQ-9 and a 27%
on the GAD–7 were previously reported, which translates
into a 1.7- and 1.5-point improvement, respectively and
standardized mean differences ˜0.5 [12] . This is consistent
with other medical fields where MCIDs defined as effect
sizes range from 0.3–0.5 [5 , 9] . Primary care services pro-
viding psychological therapy for depression and anxiety
in England currently a use a 6- and 4- point change for
the PHQ–9 and the GAD–7 respectively to capture im-
provement, which are based on the Jacobsen and Traux’s
Reliable Change Index [25 , 26] . 
The MCID is a concept, it is not mathematically de-
fined. There are various methods by which it can be
estimated, each with different modelling assumptions and
inferential objectives, meaning any comparisons between
estimates are indirect and crude. However, the flexibility
of the present method allows different levels of the prob-
ability of response to be modelled, contextualizing where
previous methods lie on the spectrum of probability of
feeling better . The mean difference method, applied in the
less severe PANDA sample, suggests an MCID of ̃ 2 points
or a SMD ˜0.5–0.6, which is comparable to previous re-
search [5 , 12] . We advocate for the ED50 to be used at
each level of baseline severity as the mean will vary from
study to study based on the severity of the sample. In-
deed, when we include the more severe CoBalT sample,
we find the mean of the ED50 estimates across patients





















Table 2. Mean change in outcome questionnaires, stratified by Global Rating of Change, study, and follow-up 



























PANDA A lot better 11.89 
(5.76) 
35 6 6.51 4.85 10.04 
(5.68) 
110 21 5.11 4.74 8.25 
(5.68) 
118 23 3.14 4.31 - - - - - 
Slightly better 164 29 3.57 4.52 168 32 2.70 4.46 143 28 2.10 3.55 - - - - 
About the 
same 
291 51 0.95 3.62 172 32 0.42 3.35 174 34 0.22 3.24 - - - - 
Slightly worse 63 11 -0.19 3.58 65 12 -1.80 4.00 66 13 -2.39 4.79 - - - - 
A lot worse 15 3 -5.60 4.93 16 3 -4.75 3.96 17 3 -6.65 5.44 - - - - 
CoBalT Better 16.48 
(5.69) 
214 49 6.51 6.00 12.59 
(6.12) 
202 49 4.04 5.40 10.81 
(6.88) 
171 45 2.23 4.96 10.42 
(6.74) 
174 48 2.34 5.03 
Same 168 38 2.19 5.10 140 34 0.61 5.17 121 32 0.52 4.89 124 34 -0.38 4.71 




PANDA A lot better 9.27 
(5.29) 
35 6 6.00 5.57 7.79 
(5.35) 
109 21 4.34 4.50 6.16 
(5.17) 
117 23 2.16 3.91 - - - - - 
Slightly better 163 29 2.96 4.55 166 31 2.28 3.69 143 28 1.69 3.71 - - - - 
About the 
same 
292 51 0.59 3.62 171 32 0.58 3.61 172 33 -0.01 3.01 - - - - 
Slightly worse 63 11 0.06 4.26 65 12 -1.09 4.03 66 13 -1.73 3.71 - - - - 
A lot worse 15 3 -4.80 4.28 16 3 -4.25 4.22 17 3 -4.24 4.96 - - - - 
CoBalT Better - - - - - 11.64 
(5.02) 
205 49 6.31 5.21 - - - - - 8.12 
(5.86) 
186 48 2.27 4.39 
Same - - - - 142 34 1.34 4.15 - - - - 135 35 -0.22 4.38 
Worse - - - - 72 17 -0.68 4.90 - - - - 65 17 -2.88 4.48 
∗Generalised Anxiety Disorder Scale-7 data was not collected at follow-up one and three. Baseline and change scores are derived from previous follow-up. 
SD - Standard deviation 
Data reported for patients with complete Global Rating of Change and change scores on each respective outcome questionnaires. 
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Table 3. The Minimal Clinically Important Difference at each level of baseline severity 
Patient Health Questionnaire -9 Generalized Anxiety Disorder Scale -7 
Baseline Score Clinical Cut-Off ED25 ED50 ED50 (%) ED75 ED25 ED50 ED50 (%) ED75 
1 Minimal 0 0 0 1 0 0 0 N.A. 
2 0 0 0 2 0 0 0 2 
3 0 0 0 2 0 0 0 3 
4 0 0 0 2 0 0 0 3 
5 Mild 0 0 0 3 0 1 20 4 
6 0 0 0 3 0 2 33 5 
7 0 1 14 4 0 2 29 5 
8 0 1 13 4 0 3 38 6 
9 0 2 22 5 0 4 44 7 
10 Moderate 0 3 30 5 0 4 40 7 
11 0 3 27 6 0 5 45 8 
12 0 4 33 6 1 5 42 8 
13 0 4 31 7 2 6 46 9 
14 1 5 36 7 2 6 43 9 
15 Severe 1 5 33 8 3 7 47 10 
16 2 5 31 9 3 7 44 11 
17 2 6 35 9 4 8 47 11 
18 3 7 39 10 5 8 44 12 
19 3 7 37 11 5 9 47 12 
20 4 8 40 12 6 10 50 13 
21 4 9 43 13 6 10 48 13 
22 5 10 45 14 - - - - 
23 6 11 48 14 - - - - 
24 7 11 46 15 - - - - 
25 7 12 48 16 - - - - 
26 8 13 50 17 - - - - 
27 9 14 52 18 - - - - 
Average across sample 1.2 3.7 23.3 6.4 1.0 3.3 28.0 6.1 
ED25, effective dose 25; ED50, effective dose 50; ED75, effective dose 75; N.A, not available. 
Table 4. Sensitivity and specificity of the Minimal Clinically Important Difference for the overall sample and stratified by study 
Patient Health Questionnaire -9 Generalized Anxiety Disorder Scale -7 
Sensitivity Specificity Sensitivity Specificity 
Overall 0.65 0.77 0.67 0.75 
PANDA 0.69 0.73 0.65 0.72 






















terms. However, the averages of our proportionate changes
(˜20–30%) is very similar to previous estimates, as might
be expected given that proportional change accounts for
baseline severity [12] . The ED estimates suggest that pre-
vious methods in research settings appear to define the
MCID as a probability of feeling better that lies somewhere
between 25% and 50%. The 6- and 4-point PHQ-9 and
GAD–7 estimates used in clinical practice appear to fall
within 50% to 75% probability of response. [25,26] Given
the ambiguity of what can be defined as a clinically ac-
ceptable probability of response, the current method alsoaffords flexibility to the user to determine which level of
probability is appropriate in a given context. 
Interestingly, patients with very low baseline severities
do not appear to require an improvement in scores to have
a 50% probability of feeling better . This initially appears
to contrast our previous research, which used Bayesian hi-
erarchical regression models and derived parameters to cal-
culate the optimum sensitivity and specificity on a Receiver
Operator Characteristics (ROC) curve and found patients
with low baselines severity needed larger changes propor-
tionate changes to feel better [12] . However, at very low
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Table 5. Standardized Mean Difference based on subgroups of the Global Rating of Change, stratified by time in PANDA 
Feeling Slightly Better Feeling the Same 
Patient Health Questionnaire -9 Change (SD) Change (SD) Crude Difference Standardized Mean Difference 
Baseline to Follow-up 1 3.57 (4.52) 0.95 (3.62) 2.62 0.64 
Follow-up 1 to Follow-up 2 2.70 (4.46) 0.42 (3.35) 2.28 0.58 
Follow-up 2 to Follow-up 3 2.10 (3.55) 0.22 (3.24) 1.88 0.55 
Generalized Anxiety Disorder Scale-7 
Baseline to Follow-up 1 2.96 (4.55) 0.59 (3.62) 2.37 0.58 
Follow-up 1 to Follow-up 2 2.28 (3.69) 0.58 (3.61) 1.7 0.47 
Follow-up 2 to Follow-up 3 1.69 (3.71) -0.01 (3.01) 1.7 0.50 









































































baselines no change vs. a 1-point improvement translates
into a large difference in proportionate change of 0% or
100%, respectively, for those with a baseline score of 1.
Therefore, this seeming discrepancy is essentially two sides
of the same coin, reflecting problems of estimation at the
lower end of the scale which manifest differently accord-
ing to the method used. This is supported by the observa-
tion that at low baseline severity the agreement between
MCID and GRC responses appears lower [12] . It may be
difficult for patients to discern a precise point at which
they experience an improvement when there is such lit-
tle scope to change in questionnaire scores. This suggests
that the measures used may not be sufficiently sensitive for
the lower ranges of severity, highlighting a need for further
exploration of how to evaluate interventions in subclinical
populations where conventional scales are at the limit of
their operability. 
Importantly, the present research also highlights a large
range of MCID estimates which suggests that previous
MCID estimates may be well suited for typical/average
populations but may not capture the MCID across all pa-
tients equally well. Previous approaches provide an easy to
implement guide but comes at a cost of 51% disagreement
between the MCID and patient reports of improvement
[12,13] . The present approach is more specific, with ˜ 23%
better agreement, but at a cost of greater complexity to im-
plement by providing an MCID for each level of baseline
severity. 
4.1. Strengths and limitations 
The present study used data from two high-quality
RCTs resulting in a large sample with clinically distinct
populations, which is critical given that the MCID is
baseline dependent. The GRC has clear face validity pro-
viding a useful patient-centered anchor [17] . 
The use of difference scores was a limitation as it ig-
nores the measurement error; however, these effects are
largely mitigated by the use of smoothing parameters in
the statistical analysis. Furthermore, the GRC is subjec-
tive in nature - the concept of recovery is complex and
unique to each patient. Clinical questionnaires commonlyfocus solely on symptoms. Responses to the GRC may
incorporate wider (mental) health and psychosocial influ-
ences, such as comorbidities, life events, or quality of life,
that may not be by captured by depression symptoms alone
[27] . Further adjustment of predictors may improve the ac-
curacy of the MCID estimates. However, these influences
are likely to be wide and varied and would therefore re-
quire very large samples and could not be completed in the
present analysis due to sample size limitations. It is also
noteworthy that we assumed that the relationship between
changes in outcome questionnaires and subjective improve-
ments, was not affected by treatment. Future research could
examine this relationship more closely and how it may be
affected by different treatments and research design char-
acteristics such as blinding. The secondary use of data re-
sulted in further limitations. PANDA and CoBalT had dif-
ferent follow-up time points potentially resulting in time-
dependent confounding. However, random effects were in-
troduced to account for repeated measurements and the
effects of time were not practically meaningful for estimat-
ing the MCID. The two studies also had differing levels
of granularity of the GRC scales which meant we could
only estimate the differences in mean change between
those feeling slightly better and the same in PANDA.
We used all of the data in our GAMM model, combin-
ing same, and worse into a single not better category to
keep in line with our previous research. [5,12] Our MCID
estimates may be over-estimated as a consequence rela-
tive to methods which exclude those who feel worse (see
Supplementary A). Although patients in both trials expe-
rienced depression and anxiety to varying degrees, the re-
sults indicate that greater changes are needed on the GAD–
7 to feel better than the PHQ–9. Both studies recruited pa-
tients on the basis of depression as the primary problem.
Changes in depression may have been perceived of greater
relative importance, requiring smaller changes to feel bet-
ter . As such, findings may not generalize to populations
experiencing anxiety as their primary or only problem. 






















































































Despite the limitations, providing estimates to measure
clinically meaningful change has important implications
for research as well as clinical practice. In the analysis of
results from clinical trials, the MCID could be applied to
each patient within the treatment arms, allowing for com-
parisons between treatments on the number of patients who
scored a change equal to or greater than the MCID. In a
similar notion, the MCID could inform evaluations in clini-
cal practice bringing greater face validity to experiences of
symptomatic improvement in conceptualizations of clinical
recovery. Equally, the within-subject change could be ap-
plied to examine between-treatment differences. Although
the MCID might be relevant to superiority and equivalence
trials, it may be particularly pertinent to non-inferiority tri-
als where an alternative treatment is cheaper, less resource-
intensive, or simpler to implement. Here, the MCID could
be used to ascertain that the difference in treatment ef-
fects does not exceed the MCID; thereby, allowing for
evaluations of cost-effectiveness that assure a newer or
cheaper treatment is not of less benefit to patients. The
ED50 MCID can inform sample size calculations by pro-
viding mean estimates of the expected change where at
least 50% of patients would experience an improvement.
They cannot inform the variance part of such calculations
which will require wider considerations on the population
studied. Baseline variability in outcome scores, however,
is the major driver of patient heterogeneity and population
level estimates of variance are easily obtainable. 
4.3. Conclusion 
The MCID contributes to our ability to assess clini-
cally meaningful change rather than statistical significance
alone. However, the research highlights the difficulty of
calibrating patient experiences with structured question-
naires, such as the need to account for baseline severity.
Here, we present an approach where the MCID is tailored
to baseline severity to fully capture the entire spectrum
of severity. Such approaches come at the cost of greater
complexity but offer greater precision. The development
and triangulation of different methods will advance our
understanding of how abstract concepts can be defined
mathematically and contextualize what different MCID ap-
proaches are measuring. 
Trial registration 
Panda and CoBalT were registered with the Controlled
Trials ISRCTN Registry: PANDA (ISRCTN84544741) and
CoBalT (ISRCTN38231611). 
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